8-K
filed March 16, 2026, 7:59 PM ET
ticker OTLK
CIK 0001649989
debt
confidence high
sentiment negative
materiality 0.85
Outlook Therapeutics, Inc. (OTLK): debt financing — Outlook Therapeutics raises $17M via Atlas note to partially repay Avondale debt; going concern warning
Outlook Therapeutics, Inc.
- Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.
- Remaining Avondale Note balance of ~$10.8M; maturity extended to Dec 31, 2026 via amendment.
- Atlas note: interest prime+3% (floor 9.5%), matures 15 months from March 16, 2026; quarterly redemption up to $3M; 7.5% exit fee.
- Supplemental risk factors state substantial doubt about going concern; cash insufficient for next 12 months.
- FDA issued third Complete Response Letter for ONS-5010 in Dec 2025; Type A meeting held March 2026 with no clear path.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Outlook Therapeutics, Inc. incurred loan of $18,360,000 with Atlas Sciences, LLC at prime rate (as published in The Wall Street Journal) plus 3% (subject to a floor maturing 15 months after the Closing.
- Instrument
- loan
- Principal
- $18,360,000
- Counterparty
- Atlas Sciences, LLC
- Rate
- prime rate (as published in The Wall Street Journal) plus 3% (subject to a floor
- Maturity
- 15 months after the Closing
- Event
- incurrence
Exact text from the filing
On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) with Atlas Sciences, LLC, a Utah limited liability company (the “Investor”), pursuant to which the Company agreed to issue to the Investor an unsecured promissory note with an original principal balance of $18,360,000 (the “Note”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Outlook Therapeutics, Inc. amended convertible notes with Avondale Capital, LLC maturing December 31, 2026.
- Instrument
- convertible notes
- Counterparty
- Avondale Capital, LLC
- Maturity
- December 31, 2026
- Event
- amendment
Exact text from the filing
In connection with the entry into the Note, we and Avondale entered into an amendment to the Avondale Note (the “Note Amendment”) to extend the maturity thereof to December 31, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Outlook Therapeutics, Inc. amended Note Amendment with Avondale Capital, LLC (effective 2026-03-16).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- Avondale Capital, LLC
- Effective
- 2026-03-16
Exact text from the filing
In connection with the entry into the Note, we and Avondale entered into an amendment to the Avondale Note (the “Note Amendment”) to extend the maturity thereof to December 31, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Outlook Therapeutics, Inc. entered into Note Purchase Agreement with Atlas Sciences, LLC valued at $18,360,000 (effective 2026-03-16).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Atlas Sciences, LLC
- Value
- $18,360,000
- Effective
- 2026-03-16
Exact text from the filing
On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) with Atlas Sciences, LLC, a Utah limited liability company (the “Investor”), pursuant to which the Company agreed to issue to the Investor an unsecured promissory note with an original principal balance of $18,360,000 (the “Note”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.